TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Biologic Innovation | TELA Bio's OviTex platform disrupts hernia repair and reconstructive surgery markets with biocompatible, cost-effective solutions aligned with industry shifts |
Financial Challenges | Despite record revenues and strong margins, TELA faces cash burn issues and ongoing losses, prompting efficiency measures to reduce expenses |
Market Dynamics | Explore TELA's positioning amidst fierce competition, including aggressive talent poaching by smaller wound care companies impacting sales performance |
Growth Trajectory | Analysts project sales reaching $105.5M by 2026, with price targets ranging from $7 to $12, reflecting cautious optimism despite near-term headwinds |
Metrics to compare | TELA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTELAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −4.2x | −0.5x | |
PEG Ratio | −0.08 | −0.30 | 0.00 | |
Price/Book | 4.2x | 2.6x | 2.6x | |
Price / LTM Sales | 1.1x | 4.1x | 3.3x | |
Upside (Analyst Target) | 204.4% | 34.6% | 42.4% | |
Fair Value Upside | Unlock | 6.6% | 7.2% | Unlock |